Abstract 247P
Background
Evaluate Role of ADC values in assessing response to chemoradiotherapy in cervix cancer & contribution of contrast MRI to identify residual disease, post-treatment completion.
Methods
Prospective observational study in 100 patients of histopathologically proven cancer of the uterine cervix. Based on clinical outcome integrating final histopathological diagnosis patients were classified as either complete response or Residual disease. Validity & reliability of PET-CT, Contrast MRI, and ADC values were checked by calculating sensitivity, specificity, PPV & NPV.
Results
Residual lesions have significantly lower ADC value than that of post-treatment changes. Mean ADC values of residual tumors: 1.26±0.238 x 10-3 mm2/s and mean ADC values of lesions due to post-treatment changes: 1.540 ±0.218 x 10-3 mm2/s (statistically significant difference in between malignant and post-treatment lesions p < 0.05). ADC sensitivity 67%, specificity 83%, PPV 35%, NPV 95 % and accuracy 81% in differentiating residual disease from post-treatment changes. PPV, NPV, sensitivity, and specificity with PET-CT was 93%, 89%, 98%, and 73%. PPV, NPV, sensitivity, and specificity of contrast MRI was 16%, 91%, 58%, and 59%.
Conclusions
Diffusion imaging differentiates residual cervix malignancies from post-treatment changes based on ADC values and can be a promising and evocative biomarker. Complimentary use of ADC and PET/CT may increase diagnostic confidence. However, the cost and logistics of MRI imaging is an important factor in routine clinical implementation especially in developing countries like India, where carcinoma cervix is associated with poor socioeconomic status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract